drugset / Trial / NCT06162286

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP

NCT06162286

Phase 3 Unknown 100 enrolled Zai Lab
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of the study is to show that in Chinese adults with CABP, a course of IV/PO treatment with omadacycline has similar clinical efficacy as the with the comparator antibiotic, IV/PO moxifloxacin. The study is designed as a bridging study, to confirm the results of the pivotal global CABP trial in an ethnically different population of Chinese.

Timeline

Start
2023-11-17
Primary completion
2025-01-01
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule Intravenous
Subject Omadacycline Small molecule Intravenous

Indications